Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

CDK inhibitor p57 (Kip2) is negatively regulated by COP9 signalosome subunit 6.

Chen B, Zhao R, Su CH, Linan M, Tseng C, Phan L, Fang L, Yang HY, Yang H, Wang W, Xu X, Jiang N, Cai S, Jin F, Yeung SC, Lee MH.

Cell Cycle. 2012 Dec 15;11(24):4633-41. doi: 10.4161/cc.22887. Epub 2012 Nov 27.

2.

CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity.

Zhao R, Yang HY, Shin J, Phan L, Fang L, Che TF, Su CH, Yeung SC, Lee MH.

Cell Cycle. 2013 Mar 15;12(6):935-43. doi: 10.4161/cc.23883. Epub 2013 Feb 19.

3.

Regulating the stability and localization of CDK inhibitor p27(Kip1) via CSN6-COP1 axis.

Choi HH, Guma S, Fang L, Phan L, Ivan C, Baggerly K, Sood A, Lee MH.

Cell Cycle. 2015;14(14):2265-73. doi: 10.1080/15384101.2015.1046655. Epub 2015 May 6.

4.

HER2-Akt signaling in regulating COP9 signalsome subunit 6 and p53.

Xue Y, Chen J, Choi HH, Phan L, Chou PC, Zhao R, Yang H, Santiago J, Liu M, Yeung GE, Yeung SC, Lee MH.

Cell Cycle. 2012 Nov 15;11(22):4181-90. doi: 10.4161/cc.22413. Epub 2012 Oct 24.

5.

Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers.

Zhao R, Yeung SC, Chen J, Iwakuma T, Su CH, Chen B, Qu C, Zhang F, Chen YT, Lin YL, Lee DF, Jin F, Zhu R, Shaikenov T, Sarbassov D, Sahin A, Wang H, Wang H, Lai CC, Tsai FJ, Lozano G, Lee MH.

J Clin Invest. 2011 Mar;121(3):851-65. doi: 10.1172/JCI44111. Epub 2011 Feb 7.

6.

Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis.

Guo H, Jing L, Cheng Y, Atsaves V, Lv Y, Wu T, Su R, Zhang Y, Zhang R, Liu W, Rassidakis GZ, Wei Y, Nan K, Claret FX.

Hepatology. 2016 Mar;63(3):898-913. doi: 10.1002/hep.28372. Epub 2016 Jan 14.

PMID:
26606000
7.

COP9 signalosome subunit 6 stabilizes COP1, which functions as an E3 ubiquitin ligase for 14-3-3σ.

Choi HH, Gully C, Su CH, Velazquez-Torres G, Chou PC, Tseng C, Zhao R, Phan L, Shaiken T, Chen J, Yeung SC, Lee MH.

Oncogene. 2011 Dec 1;30(48):4791-801. doi: 10.1038/onc.2011.192. Epub 2011 May 30.

8.

P21-activated kinase 4 regulates the cyclin-dependent kinase inhibitor p57(kip2) in human breast cancer.

Li Y, Wang D, Zhang H, Wang C, Dai W, Cheng Z, Wang G, Li F.

Anat Rec (Hoboken). 2013 Oct;296(10):1561-7. doi: 10.1002/ar.22754. Epub 2013 Jul 19.

9.

Roles of COP9 signalosome in cancer.

Lee MH, Zhao R, Phan L, Yeung SC.

Cell Cycle. 2011 Sep 15;10(18):3057-66. Epub 2011 Sep 15. Review.

10.

A new ubiquitin ligase involved in p57KIP2 proteolysis regulates osteoblast cell differentiation.

Kim M, Nakamoto T, Nishimori S, Tanaka K, Chiba T.

EMBO Rep. 2008 Sep;9(9):878-84. doi: 10.1038/embor.2008.125. Epub 2008 Jul 25.

11.

Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer.

Pateras IS, Apostolopoulou K, Koutsami M, Evangelou K, Tsantoulis P, Liloglou T, Nikolaidis G, Sigala F, Kittas C, Field JK, Kotsinas A, Gorgoulis VG.

Int J Cancer. 2006 Dec 1;119(11):2546-56.

12.

High Skp2/Low p57(Kip2) Expression is Associated with Poor Prognosis in Human Breast Carcinoma.

Yang C, Nan H, Ma J, Jiang L, Guo Q, Han L, Zhang Y, Nan K, Guo H.

Breast Cancer (Auckl). 2015 Aug 4;9(Suppl 1):13-21. doi: 10.4137/BCBCR.S30101. eCollection 2015.

13.

Downregulation of cyclin-dependent kinase inhibitor; p57(kip2), is involved in the cell cycle progression of vascular smooth muscle cells.

Nakano N, Urasawa K, Takagi Y, Saito T, Kaneta S, Ishikawa S, Higashi H, Tsutsui H, Hatakeyama M, Kitabatake A.

Biochem Biophys Res Commun. 2005 Dec 23;338(3):1661-7. Epub 2005 Oct 25.

PMID:
16259944
14.

Downregulation of p57kip² promotes cell invasion via LIMK/cofilin pathway in human nasopharyngeal carcinoma cells.

Chow SE, Wang JS, Lin MR, Lee CL.

J Cell Biochem. 2011 Nov;112(11):3459-68. doi: 10.1002/jcb.23277.

PMID:
21769918
15.

MicroRNA-21 inhibits p57Kip2 expression in prostate cancer.

Mishra S, Lin CL, Huang TH, Bouamar H, Sun LZ.

Mol Cancer. 2014 Sep 12;13:212. doi: 10.1186/1476-4598-13-212.

16.

Cortactin modulates RhoA activation and expression of Cip/Kip cyclin-dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cells.

Croucher DR, Rickwood D, Tactacan CM, Musgrove EA, Daly RJ.

Mol Cell Biol. 2010 Nov;30(21):5057-70. doi: 10.1128/MCB.00249-10. Epub 2010 Aug 30.

17.

The subunit CSN6 of the COP9 signalosome is cleaved during apoptosis.

da Silva Correia J, Miranda Y, Leonard N, Ulevitch RJ.

J Biol Chem. 2007 Apr 27;282(17):12557-65. Epub 2007 Mar 2.

18.

Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors.

Lu Z, Hunter T.

Cell Cycle. 2010 Jun 15;9(12):2342-52. Epub 2010 Jun 15. Review.

19.

Liver maturation deficiency in p57(Kip2)-/- mice occurs in a hepatocytic p57(Kip2) expression-independent manner.

Yanagida A, Chikada H, Ito K, Umino A, Kato-Itoh M, Yamazaki Y, Sato H, Kobayashi T, Yamaguchi T, Nakayama KI, Nakauchi H, Kamiya A.

Dev Biol. 2015 Nov 15;407(2):331-43. doi: 10.1016/j.ydbio.2015.07.004. Epub 2015 Jul 9.

PMID:
26165599
20.

The cell cycle inhibitor p57(Kip2) promotes cell death via the mitochondrial apoptotic pathway.

Vlachos P, Nyman U, Hajji N, Joseph B.

Cell Death Differ. 2007 Aug;14(8):1497-507. Epub 2007 Apr 27.

Items per page

Supplemental Content

Write to the Help Desk